Clinical Trial Update: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) [Phase 2]

View source ↗

Summary

Merck's sotatercept (MK-7962) completed a Phase 2 trial investigating its use in pulmonary arterial hypertension (PAH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED